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Abstract: 
Background: Small vessel disease (SVD) causes a quarter of ischaemic strokes (lacunar 
subtype), up to 45% of dementia either as vascular or mixed types, cognitive impairment and 
physical frailty. However, there is no specific treatment to prevent progression of SVD.  
Aim: We designed the LACunar Intervention Trial-2 (LACI-2) to test feasibility of a large trial 
testing cilostazol and/or isosorbide mononitrate (ISMN) by demonstrating adequate participant 
recruitment and retention in follow-up, drug tolerability, safety, and confirm outcome event 
rates required to power a phase 3 trial.  
Methods and design: LACI-2 is an investigator-initiated, prospective randomised open label 
blinded endpoint (PROBE) trial aiming to recruit 400 patients with prior lacunar syndrome due 
to a small subcortical infarct. We randomise participants to cilostazol v no cilostazol and ISMN 
or no ISMN, minimising on key prognostic factors. All patients receive guideline-based best 
medical therapy. Patients commence trial drug at low dose, increment to full dose over 2-4 
weeks, continuing on full dose for a year. We follow-up participants to one year for symptoms, 
tablet compliance, safety, recurrent vascular events, cognition and functional outcomes, Trails 
B and brain MRI.   LACI-2 is registered ISRCTN 14911850, EudraCT 2016-002277-35.   
Trial Outcome: Primary outcome is feasibility of recruitment and compliance; secondary 
outcomes include safety (cerebral or systemic bleeding, falls, death), efficacy (recurrent 
cerebral and cardiac vascular events, cognition on TICS, Trails B) and tolerability. 
Summary: LACI-2 will determine feasibility, tolerability and provide outcome rates to power a 
large phase 3 trial to prevent progression of cerebral small vessel disease. 
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Introduction: 
Stroke and vascular dementia are increasing in prevalence,1 have enormous economic and 
societal costs, share many risk factors, and are major Government targets for health 
improvement.2,3 Cerebral small vessel disease (SVD) is a central link between stroke and 
dementia.4 It accounts for 20-25% of clinical strokes as either recent small subcortical or 
‘lacunar’ infarcts5 (hereafter referred to as ‘lacunar ischaemic stroke’) and most intracerebral 
haemorrhages in older people,6 and up to 45% of all dementias, alone or combined with 
Alzheimer’s disease.7 Patients presenting with a lacunar ischaemic stroke are often younger 
than with other stroke subtypes,6 and about a third experience post-stroke cognitive 
impairment or dementia8,9 which may restrict their independence, including ability to return to 
work.9   
 
The causes of lacunar ischaemic stroke are still poorly understood.4 Most appear due to an 
intrinsic cerebral perforating arteriolar disease. This includes impaired vasoreactivity, 
increased blood-brain barrier (BBB) permeability and perivascular inflammation, all causing 
brain damage4 visible on magnetic resonance imaging (MRI) including white matter 
hyperintensities (WMH), lacunes, prominent perivascular spaces and microbleeds. 
Additionally, the damaged endothelium may precipitate local thrombosis and ischaemia, which 
worsens the damage.4   
 
Despite the profound health impacts, few RCTs specifically targeted either SVD lesion 
progression or lacunar stroke.10 The largest trial in lacunar ischaemic stroke, the Secondary 
Prevention of Small Subcortical Stroke (SPS3) trial, tested 3.4 years of aspirin+clopidogrel vs 
aspirin11 and 3.7 years of target vs guideline blood pressure (BP) reduction12 in 3020 lacunar 
ischaemic stroke patients, to prevent recurrent stroke and cognitive decline. The 
aspirin+clopidogrel vs aspirin arm stopped early due to increased death;11 target (vs guideline) 
BP lowering was consistent with a small reduction in recurrent stroke, but neither it nor 
aspirin+clopidogrel vs aspirin reduced cognitive decline.13   
 
Given the long timeline to develop new drugs, available licensed drugs with relevant actions 
should be evaluated.10 Prostacyclin (PGI2)-cyclic AMP-phosphodiesterase3 pathway or Nitric 
oxide (NO)-cyclic GMP-phosphodiesterase5 modulators may improve vasodilatation, reduce 
inflammation and smooth muscle hypertrophy and improve cerebral endothelial integrity.10 
Amongst several drugs licensed in Europe, cilostazol and isosorbide mononitrate show 
promise; two drugs with complementary actions could have synergistic effects.  
Cilostazol, a phosphodiesterase 3-inhibitor (PDE3-inhibitor), enhances the PGI2-cAMP 
pathway, with weak antiplatelet effects (so low bleeding risk).14 Routine cilostazol use reduced 
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dementia incidence in the Taiwanese registry,15 reduced infarct size16 and improved myelin 
repair in animal models,17 and has been trialled for secondary stroke prevention in more than 
6400 patients.18-22  Trials where >50% of participants had lacunar stroke (n=4780) found long-
term cilostazol (vs placebo or aspirin) reduced recurrent stroke (OR 0.62, 95%CI 0.49-0.77) 
with no evidence of an increase in cerebral haemorrhage (OR 0.52, 95%CI 0.36-0.75), or 
death (OR 0.90 95%CI 0.53-1.52) over median one year treatment. However, there are limited 
randomised data on cilostazol’s effects on cognition or imaging features of SVD, and data are 
from Asia-Pacific countries where the epidemiology and risk factors may differ from western 
patients. 
Isosorbide mononitrate (ISMN) is an NO-donating organic nitrate that enhances vasodilation, 
is widely used in ischaemic heart disease with a known safety profile and has no antiplatelet 
activity.23 NO maintained cerebral perfusion short term after subacute stroke,24 but drugs that 
increase NO availability are rarely used in stroke.25  
 
The LACI-1 trial26 tested short-term dose escalation protocols for cilostazol and ISMN 
individually and together, tolerability and early markers of safety and efficacy in patients with 
lacunar stroke.27 LACI-1 recruited 56 patients in two centres, showed that headache, nausea, 
palpitations were common pre-randomisation, increased on starting either trial drug, but by 
incrementing the dose slowly, symptoms returned to background levels within two weeks.27 
Most patients achieved the target dose27 without safety concerns.28 The LACI-2 trial aims to 
determine if cilostazol and ISMN, alone or together, are tolerated at the target dose for a year, 
provide feasibility, safety and efficacy data, prior to proceeding to a large phase III trial. 
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Methods   
LACI-2 is a phase IIb randomised, partial factorial, open label, blinded end-point trial, aiming 
to recruit 400 patients from UK Stroke Network Centres, with follow-up to one year. In addition 
to experience from LACI-1, LACI-2 trial design benefitted from:  
• a National Institutes of Health Research (NIHR) Stroke Research Network (SRN) 
Portfolio Development Expert Writing Group (members*), which discussed trial design 
options in detail; 
• the USA NIH-funded SPS3 trial11,12 (3020 patients with lacunar stroke): Chief 
Investigator [CI] O Benavente*, which informed on recruitment and outcome event 
rates;  
• the CSPS, CSPS-2 (3740 patients)18,20 and CSPS-3 trials22 testing cilostazol to prevent 
stroke in Japan: CI K Toyoda, informed on cilostazol dose and escalation to increase 
tolerability; 
• monogenic SVDs:29 CI H Chabriat*, informed on timing and practicality of potential 
outcome assessments, and the relative merits and rates of functional, cognitive and 
other outcomes to optimise sensitive outcomes against the burden of assessments on 
the participants; 
• the PRESERVE trial:30 CI H Markus*, informed on approaches to patient recruitment, 
cognitive assessments, and MRI rates; 
• the PODCAST trial:31 CI P Bath*, Co-CI LACI-2, informed on minimisation algorithms, 
data collection, likely availability of informants, approaches to loss of mental capacity 
during the trial, cognitive assessments and frequency of outcome assessments; 
• CROMIS- 2 and the Microbleeds International Collaborative Network,32, 33 informed on 
clinical and imaging assessments, frequency and practicalities of potential outcome 
assessments. 
 
The UK SRN Prevention Clinical Studies Group strongly supported testing cilostazol and ISMN 
in SVD prevention and many UK Clinical Research Network Centres expressed interest in 
joining LACI-2. 
 
Patients undergo guideline-based investigations as per usual stroke prevention practices in 
the UK including carotid and cardiac investigations and for other rarer causes in young strokes 
as appropriate.    
 
Patients are eligible if they are independent in activities of daily living, have capacity to give 
consent, are aged over 30 years, have suffered a minor stroke with clinical features compatible 
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with a lacunar syndrome (most frequently, but not limited to, a pure motor hemiparesis, pure 
sensory stroke, ataxic hemiparesis, sensorimotor stroke, or dysarthria-clumsy hand 
syndrome; designated as the ‘index stroke’) and have, on contemporaneous CT or MRI brain 
imaging, either a visible relevant recent small subcortical (lacunar) infarct or no alternative 
pathology to explain symptoms (Table1). There is no maximum time limit for recruitment 
because a) lacunar stroke indicates the presence of SVD which is a longstanding condition, 
b) recurrent stroke after lacunar stroke and signs of SVD progression are thought to occur 
slowly and inexorably (in contrast to atherothromboembolic stroke where the risk of recurrence 
is immediate then declines), c)  to avoid guideline dual antiplatelets and minimise the burden 
of participation on the patient soon after the stroke, d) since both drugs are likely to affect long-
term chronic vascular dysfunctions, e) to increase recruitment by avoiding clashes with high 
periods of recruitment to acute treatment and secondary prevention trials and f) since any time 
limit would be very arbitrary after considering all the above. However, time after stroke is 
accounted for in minimisation and will be accounted for in the statistical analysis.  
 
Exclusion criteria include other significant active neurological illness, alternative pathologies 
visible on imaging (cortical infarct, subcortical infarct exceeding 2cm diameter likely to be large 
artery, haemorrhage, tumour, etc), athero- or cardio-embolic source requiring specific 
treatment, renal or hepatic impairment, unlikely to complete follow-up due to illness or location, 
current enrolment in another Clinical Trial of Investigational Medicinal Product (CTIMP), and 
other general and specific reasons listed in Table 1. Co-enrolment is allowed in non-CTIMPs.   
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Table 1. Inclusion and exclusion criteria 
Inclusion criteria Exclusion criteria 
• Independent in activities of daily living (modified Rankin ≤2),  
• Capacity to give consent,  
• Aged over 30 years,  
• Minor stroke with clinical features compatible with a lacunar 
syndrome. Contemporaneous brain imaging shows either: 
a) a recent, relevant (in time and location) acute small subcortical 
infarct on MRI diffusion imaging,  
b) or MR FLAIR, T2 or T1 MR imaging or CT brain imaging shows 
a recent-appearing small subcortical infarct in a relevant 
location (i.e. no cavitation or ex-vacuo effect, may be slightly 
swollen, ill-defined edges), 
c) or MR FLAIR, T2 or T1 MR imaging or CT brain imaging shows 
a new small subcortical infarct, in a relevant location, appearing 
between a scan obtained prior to, or just after, the stroke and 
one done hours to days after the stroke, 
d) or if there is no visible acute small subcortical infarct on MR or 
CT brain imaging, then there is no alternative pathology as a 
cause for stroke (i.e. no acute cortical infarct, no acute intra-
cerebral haemorrhage, no stroke mimic such as tumour, 
subdural haematoma). 
General:  
-Other significant active neurological illness e.g. recurrent seizures, 
multiple sclerosis, brain tumour (well-controlled epilepsy present prior 
to the stroke, a single seizure at onset of the stroke or provoked 
seizure is not an exclusion);  
-Modified Rankin ≥3; 
-Formal clinical diagnosis of dementia; 
-Hypotension, defined as sitting systolic blood pressure <100mmHg; 
-Unable to swallow tablets; 
-Planned surgery during the trial period; 
-Other concurrent life threatening illness; 
-Unlikely to be available for follow-up;  
-History of drug overdose, attempted suicide, significant active mental 
illness; 
-Pregnant or breastfeeding women, women of childbearing age not 
taking contraception;  
-Renal impairment (creatinine clearance <25 ml/min); 
-Hepatic impairment;  
-Current enrolment in another Clinical Trial of Investigational Medicinal 
Product (CTIMP); 
-Unable to tolerate, or contraindication to, MRI. 
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 Specific to one or other but not both trial drugs (note patients with a 
contraindication to one trial drug can still be randomised to the other 
trial drug):  
-Definite indication for, or already prescribed, or contraindication to, a 
trial medication;  
 
Cilostazol: 
-Bleeding tendency, e.g. known platelets<100, active peptic ulcer, 
history of intracranial haemorrhage (not asymptomatic haemorrhagic 
transformation of infarction, or a few microbleeds); 
-Prescribed anticoagulant medication or dual antiplatelet drugs; 
-Prescribed prohibited medications including omeprazole (can be 
switched to other proton pump inhibitor), erythromycin, clarithromycin, 
diltiazem, some antifungal or antiviral agents; 
-Active cardiac disease (atrial fibrillation, myocardial infarct in last six 
months, active angina, symptomatic cardiac failure). 
 
Isosorbide mononitrate: 
-Lactose intolerance, where site uses ISMN preparations which 
contain lactose monohydrate; 
-prescribed prohibited medications including avanafil, sildenafil, 
tadalafil, vardenafil. 
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Consent:  
Participants must have capacity and consent is taken from them for the trial and for secondary 
data uses; consent is taken from a relative or other informant to provide outcome data. 
 
Intervention:  
isosorbide mononitrate 40-60mg (or equivalent formulation) daily only; cilostazol 200mg daily 
only; or both isosorbide mononitrate 40-60mg and cilostazol 200mg daily. The range of ISMN 
doses is allowed to account for different formulations provided in hospital pharmacies. The 
trial is open-label since placebo tablets were not available in the UK and masking by 
encapsulation was impractical and expensive due to dose escalation and factorial trial design. 
However, outcomes including structured symptom questionnaires, ascertainment of clinical 
outcomes and MRI analysis are collected by individuals blinded to treatment allocation. 
Participants with indications for or contraindications to one drug can be randomised to the 
other drug only. The partial factorial design allows testing of both drugs when given alone and 
together.  
 
Comparator:  
Best medical guideline stroke prevention therapy as per UK guidelines, which include neither 
cilostazol nor ISMN. Throughout the trial, participants continue to take their normal prescribed 
medication, information on which is collected at randomisation. 
 
Randomisation, minimisation:  
Randomisation is by central computer-generated allocation at the University of Nottingham 
after recording key patient variables and minimisation data. Minimisation uses key prognostic 
factors including: age, sex, stroke severity (National Institute of Health Stroke Scale, NIHSS), 
dependency resulting from the stroke, systolic BP ≤/>140, smoker status, time after stroke, 
and years of education. Years of education give an estimate of pre-morbid cognitive ability 
and predicts post-stroke cognitive impairment;9 BP and smoking predict recurrent stroke; 
delay since stroke reflects disease activity; age, sex and stroke severity are standard 
minimisation variables.27 This approach ensures concealment of allocation, minimises 
differences in key baseline prognostic variables, and improves statistical power. 
Randomisation is not minimised by Centre because this may result in high rates of allocation 
prediction, but a pre-specified post-hoc analysis by centre will be performed to investigate and 
adjust for heterogeneity of treatment effect by centre.
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Dispensing:  
Participants are allocated in a 1:1 ratio to cilostazol versus no cilostazol and to ISMN versus 
no ISMN, resulting in a partial factorial comparison of cilostazol versus ISMN versus both 
drugs versus neither drug. The algorithm generates a unique trial ID and number 
corresponding to a prescription of allocated trial treatment, which is prepared and dispensed 
by the local Pharmacy.  
 
Drug initiation and maintenance:  
After randomisation, patients are given instructions to start on a low dose and escalate to 
target dose over two-to-four weeks. For ISMN, 25mg once daily in the first week, 40-60mg 
daily in the second week and thereafter. For Cilostazol, 50mg once daily for the first week, 
twice daily in the second week rising to 100mg twice daily over the next two weeks until 
participants are on their full dose by one month, remaining on full dose for the rest of the year. 
Escalation can proceed more slowly if necessary. Participants can remain on less than full 
dose if they are unable to tolerate the full dose, since some drug may be better than no drug 
and dose is recorded.  
 
Assessments:  
At baseline, the study researcher records details of the presenting stroke, past medical history, 
medications, socioeconomic status, education, lifestyle factors, neurological findings, brain 
imaging findings (index stroke, background WMH, lacunes, microbleeds), blood pressure, 
cognitive testing (Montreal Cognitive Assessment, Trails B), haematology and biochemistry 
(Table 2).  
 
After commencing trial treatment, local researchers telephone the participants at 1-2 and 3-4 
weeks post randomisation, with intermediary phone calls as necessary, to advise on dose 
escalation, symptoms, events, check they have achieved full dose or are established on a 
lower tolerated dose by four weeks.  
 
At six and 12 months, central trial staff (Edinburgh, Nottingham), masked to treatment 
allocation, perform follow up by postal questionnaire and phone. Additionally, at 12 months, 
the patient attends their local trial centre for Trails B and brain MRI (to assess SVD lesion 
burden, new stroke lesions). Information recorded at six and 12 month follow-up includes 
symptoms, recurrent ischaemic or haemorrhagic stroke or transient ischaemic attack (TIA), 
cardiac events, smoking status, current medications, modified Rankin scale (mRS), Stroke 
Impact Scale,34 and separately the amount of trial medication (Table 2). Date and cause of 
death are recorded. Participants are encouraged to contact their local Trial Centre to record 
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vascular events occurring between follow-up points. Unused drug is returned to pharmacy at 
the participating hospital for accountability and destruction at the end of the trial.  
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Table 2: Study Assessments 
Assessment 
Prior to 
Baseline 
Visit 1 
Baseline 
 Week 
1-2 FU 
Week 
3-4 FU 
 6 
month 
FU 
 12 
month 
FU 
Screening for eligibility and 
Consent1;  
X      
Confirm and document ongoing 
consent  
 X     
Medical including drug history  X     
Assess MR or CT diagnostic scan 
and send a copy to Edinburgh 
 X     
Randomisation  X     
Haematology (full blood count) 
and Biochemistry (urea, 
electrolytes, creatinine)  
 X     
Blood Pressure   X    X* 
Cognitive test: years of education;  
Montreal Cognitive Assessment 
(MOCA),  
timed Trail Making Test B 
 X     
Dispense trial medication2  X   X  
Record symptoms; medication 
history and IMP adherence 
  X X X X 
Record recurrent vascular events, 
mRS, TICS, TMOCA, SIS, ZUNG, 
* timed Trail Making Test B 
    X X* 
IQCODE (post/phone)       X 
Follow-up brain MRI      X 
Health Economics data: EQ-5D-
5L, EQ-VAS 
     X 
Adverse event reporting as 
necessary 
  X X X X 
1Consent will be obtained before the data collection procedures commence or randomisation 
is performed. Randomisation occurs at the end of the baseline visit. * at 12 months in some 
centres only. 2 Dispensing in 3-monthly intervals is allowed. 
FU=follow-up, SIS=Stroke Impact Scale, TICS= Telephone Interview for Cognitive Status, 
TMOCA= telephone MOCA.  
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Brain imaging:  
All MR or CT scans performed for stroke diagnosis, to assess new neurological events during 
the trial, and at one-year follow-up, are collected centrally, anonymised, for blinded 
assessment. MRI at one year must include diffusion-weighted imaging (DWI), T2-weighted, 
fluid attenuated inversion recovery (FLAIR), susceptibility-weighted (blood sensitive), and T1-
weighted sequences (exemplar sequences are provided). Scans are rated, blind to patient 
characteristics and treatment allocation, to assess the index infarct location, size, WMH, 
lacunes, old cortical infarcts, old haemorrhages, microbleeds, siderosis, perivascular spaces 
and brain atrophy, with validated scores using a web-based system.5  
 
Adverse Events are recorded as serious (SAEs), reported to the Sponsor, if they result in 
hospitalisation, persistent disability, death, or are life threatening. Recurrent vascular events 
(stroke, myocardial infarction (MI), TIA) and bruising, bleeding or other types of haemorrhage 
are collected as outcomes, not SAEs. Serious adverse reactions (SARs) and suspected 
unexpected serious adverse reactions (SUSARS) are also reported. Adverse events (AEs) 
that are common in patients with stroke and do not meet criteria for seriousness or drug related 
are recorded.  
 
Outcomes:  
The primary outcome is feasibility, i.e. that eligible participants can be identified correctly, in 
sufficient numbers, enrolled and >95% retained in follow-up at one year, to achieve target 
sample of 400 participants in 24 months in the UK. The secondary outcomes are tolerability 
(can patients tolerate trial medication at least in half dose for up to a year?), safety (systemic 
or intracranial bleeding, vascular and non-vascular causes of death) and efficacy (stroke, TIA, 
myocardial ischaemia, cognitive impairment and dementia).  
 
Sample size:  
Data to estimate sample size were limited. Based on LACI-1, we estimated that 75% of 
participants would take trial medications, in at least half dose, up to one year. We calculated 
mean annual event rates (Table 3) from trials (SPS3,11 lacunar participants in ENOS,25 IST-
3,35 of cilostazol18,20,36) and observational data (LADIS;37 our9,38,39 and other40 studies). We 
expect deaths including vascular deaths of median 2.0% pa, with 4% being the upper 95% CI 
of 2% in 400 participants.11 We propose that the absolute risk of death, including fatal 
haemorrhage, will not exceed 4% per year on trial drugs versus no trial drugs, given in addition 
to guideline drugs, and will not increase bleeding or ischaemic SVD lesions significantly (at 
the p<0.01 level) on MRI. LACI-2 therefore has a sample size of 400. Considering a future 
14 
 
Phase III trial, recurrent stroke 2.5% pa, MI 0.6% pa and vascular death 1.8% pa,6,11 (major 
adverse cardiovascular events, MACE are infrequent); in contrast, new cognitive impairment 
and dependency approximate 16% and 15% respectively at one year,8,40,41 and are important 
to healthcare professionals, patients and carers,9 thereby justifying their inclusion in a 
composite primary outcome. Thus the combined rate of recurrent stroke, MI, death, cognitive 
impairment and dependency was estimated at 40-50% at one year after enrolment.42 We 
estimate main Phase III trial sample size at 1100 (Table 4), assuming 80% power, alpha 5%, 
10% loss to follow-up, composite event rate (45%) and conservative estimate of cilostazol 
effect (20% RRR is the lower 95% CI of effect; there were no data for ISMN). A primary 
outcome including MRI SVD progression was considered, but at least 15% of participants miss 
repeat MRI, sample sizes were similar or larger due to variance in WMH change,39,43 the cost 
of an MRI-based trial is much higher and the WMH intermediary measure is less relevant to 
patients.  
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Table 3 Annual absolute risks (%) of outcome events after lacunar stroke – see text for data 
sources. 
Vascular 
death 
Non-
vascular 
death 
Non-fatal 
ischaemic 
stroke or 
TIA 
Non-
fatal 
ICH 
MI MACE Dependent 
(mRS 3-5) 
Any 
cognitive 
impairment 
Dementia 
 
1.8 0.5 2.5 0.5 0.6 3 15 30 15 
MI = myocardial infarction, ICH = intracerebral haemorrhage, mRS = modified Rankin Scale, 
MACE = major adverse cardiovascular events  
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Table 4. Sample size for composite outcome in main trial, estimated event rates - see text 
for data sources. 
Composite model A B Ci Cii D 
Composite 
outcome for Phase 
III includes: 
MACE, 
dementia, non-
vasc death, 
new MR signs 
MACE, 
dementia, 
death 
MACE, cog, 
dependency, 
death 
 MACE, cog 
imp, 
depend, all 
death 
1-beta (power) 80% 80% 80% 80% 80% 
Event rate, control, 
pa 
50% 10% 30% 30% 45% 
Relative risk 
reduction 
20% 20% 20% 30% 20% 
Event rate, active, 
pa 
40% 8% 24% 21% 36% 
Total sample size 950 6626 1784 778 976 
Total trial size, inc 
losses 
1250 7400 2000 900 1100 
Assume: 1:1 randomisation and Fleiss adjustment; alpha 5%; primary outcome incomplete in 
10% 
17 
 
Statistical analysis:  
A Statistical Analysis Plan (SAP) will be published prior to recruitment ending, blinded to data. 
A brief summary of planned analyses are as follows. We will compare cilostazol v no cilostazol, 
ISMN v no ISMN, cilostazol and ISMN v neither, by intention to treat (ITT) analysis. The 
proportion of patients achieving and sustaining target dose and adverse symptoms will be 
assessed using odds ratios. ITT analysis will use logistic regression adjusted for minimisation 
variables and other baseline prognostic variables (to maximise power44) including SVD score, 
age, and cilostazol+/-ISMN versus control on efficacy and safety outcomes, with secondary 
tests of subgroup interactions. Ordinal logistic regression will be used for ordinal categorical 
outcomes (e.g. mRS) to increase power.45 To analyse safety, we will use Kaplan-Meier and 
Cox proportional regression for time-to-event outcomes of death, recurrent stroke, MI; binary 
logistic regression for SAEs, recurrent stroke, MI, and in those completing 12 month MRI, 
microbleeds, siderosis, new infarcts, and WMH burden.  
 
Trial and data management  
LACI-2 has an operational management committee meeting alternate weeks, a Trial Steering 
Committee (TSC) with an independent chair, two scientific advisors, participant, funder and 
sponsor representatives meeting six monthly, a Data Monitoring Committee (DMC) with four 
independent members meeting yearly, and an International Advisory Board that provides 
informal advice. The Sponsor, the University of Edinburgh/NHS Lothian joint Academic and 
Clinical Central Office for Research and Development (ACCORD) approves all trial 
procedures and provides monitoring. The trial is managed from the Edinburgh Clinical Trials 
Unit, registered with UKCRC. The secure, password-protected, electronic database and case 
record form is held at the University of Nottingham; statistical support is provided by the 
Nottingham Stroke Trials Unit and UKCRC-registered Nottingham Clinical Trials Unit; image 
data management and analysis is at the University of Edinburgh. Only the DMC members see 
unblinded data during the trial. Members of each group are listed in the Appendix. 
 
 
Discussion 
LACI-2 is testing drugs that aim to improve the endothelial dysfunction seen in lacunar 
ischaemic stroke, given for one year. LACI-2 builds on experience in LACI-1 including 
inclusion and exclusion criteria, data collection, randomisation and statistical analysis, has a 
similar TSC, the same DMC and International Advisory Boards, to enhance and retain 
knowledge and experience. LACI-2 will provide methods for balancing randomisation, 
streamlining of follow-up and reliable data on key event rates for lacunar stroke/SVD trials, 
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preparatory to a Phase III trial of these drugs for definitive efficacy and safety data. LACI-2 
aims to promote more personalised approaches to brain vascular disease by recognising and 
addressing key mechanistic and susceptibility differences between ischaemic stroke 
subtypes. 
 
LACI-2 is pragmatic; we faced several practical issues in designing the trial and recognise that 
some of our decisions were, of necessity, empirical since there have been few trials in lacunar 
stroke to guide design. In LACI-1, target sample 60 patients in two centres, recruitment time 
was reduced by 8 months and the total cost by £85000 (equivalent to a third of total available 
funding) using enrolment based on CT or MRI compared with only allowing enrolment based 
on MRI.27 Although an MRI-based trial could be more specific for lacunar stroke, we showed 
that it would delay trial completion by at least 33% thus inflating staff costs significantly, it 
would exclude patients unable to tolerate MRI, and delay scientific progress since the time to 
finding a treatment for lacunar ischaemic stroke would take much longer. Since no imaging 
modality is perfect, and not all acute ischaemic lesions are visible on MRI even with diffusion 
imaging (e.g. 30% of patients with lacunar or mild cortical stroke do not have an acute lesion 
on DWI yet have similar rates of recurrent stroke, functional and cognitive impairments46) 
appropriate use of CT and MRI can exclude alternative causes of symptoms, and CT can 
detect moderate to severe WMH, lacunes, atrophy, and old stroke lesions including 
differentiating some old haemorrhages from old infarcts.47,48 LACI-2 also does not set a 
maximum time from stroke to recruitment after consideration of pathological (lacunar stroke 
due to intrinsic cerebral arteriolar pathology indicates the presence of a chronic condition, 
SVD, and disease progression is thought to occur steadily and slowly), pharmacological 
(putative effects of cilostazol and ISMN are on chronic vascular dysfunctions), and practical 
reasons (avoid subacute post-stroke period when guideline dual antiplatelet drugs are used, 
and minimise clashes with other acute treatment and short term secondary prevention trials).  
 
There is no placebo in LACI-2 since, after considerable searching, none was available, but 
central follow-up and MRI are blinded to allocation. LACI-2 encourages best medical 
management in all patients including good blood pressure control using guideline medications. 
Good blood pressure control may help reduce WMH progression49 and prevents stroke. LACI-
2 is therefore testing cilostazol or ISMN or both plus best medical management versus best 
medical management alone.  
 
LACI-2 started recruiting in March 2018 in one site, had opened 26 sites and recruited 258 
participants by February 2020. Apart from delays in opening sites due to the large 
administrative burden of clinical trials, it is on course to complete recruitment by Dec 2020, to 
19 
 
complete follow-up by Dec 2021, and report in spring 2022. The DMC have met twice (August 
2018 and 2019) and recruitment continues. To the best of our knowledge, LACI-2 appears to 
be the only ongoing trial specifically testing agents for long term prevention of recurrent 
lacunar stroke, MACE and worsening of SVD. It is one of only five trials listed in the 
Alzheimer’s Drug Discovery Foundation Report 2018 (Drug testing in Dementia, 
https://www.alzdiscovery.org/research-and-grants/clinical-trials-report) that is addressing 
prevention of vascular dementia, and the only one at Phase IIb level. We hope that LACI-2 
will help inform the future design of trials in lacunar stroke and other clinical presentations of 
SVD. 
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Figure 1 CONSORT diagram 
 
 
 
 
 
 
 
 
 
[INSERT IMAGE HERE] 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Diagnostic MR or CT brain scan assessment (Baseline) refers to a visual assessment of the scan that has 
already been performed as part of the patient’s routine stroke clinical assessment and diagnosis. Features 
present on the scan are scored for their presence and severity to create a total sum of small vessel disease 
score. This is used in the minimisation algorithm.  
Dispensing may be at 3-monthly intervals if preferred in particular centres. 
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